[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
March> 1, 2008

Time to Nip “Seeding Trials” in the Bud

Arch Dermatol. 2008;144(3):403-404. doi:10.1001/archderm.144.3.403

In October 2005, clobetasol, 0.05%, spray (Clobex spray; Galderma Laboratories LP, Fort Worth, Texas), received US Food and Drug Administration (FDA) approval for treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area in patients 18 years or older.1 A few months thereafter, I received a brochure inviting me to be an investigator in a study of Clobex spray that was called “CoBRA,” an acronym for Community-Based Research Assessment.2 “Join Us as an Investigator,” the brochure read.2(p1) It continued2(p2):

First Page Preview View Large
First page PDF preview
First page PDF preview
×